Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale RICHMOND, Va. (

Aditxt, Inc. (NASDAQ:

ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

RICHMOND, Va. (Aug. 18, 2023) -

Aditxt, Inc, (NASDAQ: ADTX) ("Aditxt" or the "Company"), a

global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate

the immune system, is pleased to provide an important update regarding its innovation programs

and strategic M&A initiatives.

At Aditxt, our DNA is focused on bringing some

of the most needed and promising health innovations and solutions to life in a faster, more efficient way. We believe strongly in the

power of precision medicine, precision diagnostics and monitoring, precision prevention, and precision treatment. People deserve better

than a one-size-fits-all approach to disease prevention, diagnostics, and treatments-in every area of health, including autoimmune

diseases, oncology, neurology, and viral infections.

As we near the end of the third quarter of

2023 and look ahead to 2024, we are focused on expanding our portfolio to include:

For Q2 2023 and the first half of the Q3 2023,

we have been heavily focused on ongoing conversations around promising innovations. We also mutually agreed to terminate the non-binding

letter of intent with Natural State Genomics and Natural State Laboratories.

Since the founding of Aditxt, we have believed

that commercializing health innovations deserves a new approach driven by stakeholders. For far too long, game-changing innovations never

see the light of day. Highly promising innovations, drug molecules, therapeutics, screening devices, or pieces of hardware or software,

are tabled due to lack of critical infrastructure, expertise, and resources needed to survive and thrive-including, operations,

finance, M&A, global partnerships, content and marketing, access to labs and research facilities, and more. We believe that the Aditxt

model offers the foundation innovations needed to succeed.

Finally, Aditxt was built and designed to harness

the power of global capital markets and partners-from medical research institutions to software and hardware companies, manufacturing,

and commercialization. As we expand, so does our ability to accelerate innovation. We are committed to advancing healthcare through innovation

and precision medicine. At Aditxt, we strive to make promising innovations possible, together.

"Aditxt takes a stakeholder-driven approach

to developing and deploying some of the most promising health innovations such as Pearsanta's immune monitoring platform, and Adimune's

immune modulation therapeutic," says Amro Albanna, Aditxt CEO, Chairman and Co-Founder. "Our goal is to get our current programs

to reach key clinical or commercial stage and expand our portfolio of innovations to address additional markets such as oncology and

Adimune, Inc.'s immune modulation technologies

are designed to retrain the immune system to restore tolerance in autoimmune diseases and allergies, and to induce tolerance in allogeneic

skin transplantation.

Program Highlights and Next Steps

Leadership Weighs In

"This is an exciting time for Adimune.

ADI-100 is now part of an investigator sponsored study at the Mayo Clinic this year in patients with Stiff-Person Syndrome, a

very severe progressive central nervous system autoimmune disorder," says Adimune co-CEO Joachim-Friedrich Kapp, M.D.,

Ph.D. "Once the stability program is completed, we intend to finalize the CTA documents and apply for regulatory approval to perform

clinical trials in two additional indications, T1D and psoriasis. We are optimistic that the findings in the human trials will confirm

what has been established in the vast number of animal safety and efficacy studies."

anytime and anywhere"

Pearsanta, Inc. is committed

to building a "lab testing anytime and anywhere" model through three channels:

Traditional lab developed

tests ("LDT"s); Point of Care ("POC") devices (i.e., "lab on a chip,"); and Direct to Consumers ("DTC")

Program Highlights and Next Steps

Leadership Weighs In

"Pearsanta's lab testing platform

is a paradigm shift in how consumers can access their healthcare on demand for immediate care," says Ernie Lee, Head of Pearsanta.

"As an example, positive lab test results from UTIs, Covid, flu, RSV, and STIs respond most effectively when treatments are started

within a few days of symptoms. Through the platform, you could potentially be tested, see a health care provider, receive a prescription

for a medication, if one is needed, and have the prescription filled-all in one encounter."

Antiviral therapeutics

Adivir, Inc. is focused on catalyzing discoveries

that prevent and cure infectious diseases.

Program Highlights and Next Stage

Aditxt, Inc. (NASDAQ:

ADTX) is a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor

and modulate the immune system. Headquartered in Richmond, Virginia, with operations in Silicon Valley, California, and New York. Aditxt's

mission of "Making Promising Innovations Possible, Together" is defined by our growing ecosystem of research institutions,

global industry partners, and shareholders who inform and inspire our mission. Aditxt's diverse innovation portfolio includes:

Adimune , Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection,

autoimmunity, and allergies; Adivir , Inc., focused on identifying, developing and commercializing new ways to treat infectious

diseases; and Pearsanta , Inc., which offers personalized immune monitoring for a wide range of health conditions, including hereditary

cancer, wounds and cardiomyopathy.

For more information, visit the Company's

Forward-Looking Statements

Certain statements in this press release

constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements include statements

regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the

Company's ongoing and planned product and business development; the Company's ability to finance and execute on its strategic M&A

initiatives; the Company's ability obtain the necessary funding and partner to commence clinical trials; the Company's intellectual

property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's

results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the Company's ability

to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company.

Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by

these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more

fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions

of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission.

All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking

statements, whether as a result of new information, future events or otherwise, except as required by law.

Media and Investor Relations Contact: